When we co-exposed mouse lung cancer cells to different concentrations of TCPOBOP plus paclitaxel at the inhibitory concentration (IC50), the CAR agonist improved paclitaxel anti-tumor efficacy dose-dependently, reducing cell viability by almost 40% when compared to that in cells treated with Paclitaxel alone (p<0.05; Fig. 1). This evidence concerns the gene CXADR and lung carcinoma.